SEARCH

SEARCH BY CITATION

References

  • 1
    Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med2009; 360:26052615.
  • 2
    Shinde V, Bridges CB, Uyeki TM et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009. N Engl J Med2009; 360:26162625.
  • 3
    Garten RJ, Davis CT, Russell CA et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science2009; 325:197201.
  • 4
    Smith GJ, Vijaykrishna D, Bahl J et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature2009; 459:11221125.
  • 5
    Vincent AL, Lager KM, Ma W et al. Evaluation of hemagglutinin subtype 1 swine influenza viruses from the United States. Vet Microbiol2006; 4:212222.
  • 6
    Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med2009; 361:19451952.
  • 7
    LaBoissiere S, O’Hare P. Analysis of HCF, the cellular cofactor of VP16, in herpes simplex virus-infected cells. J Virol2000; 74:99109.
  • 8
    McCullers JA, Van De Velde LA, Allison KJ, Branum KC, Webby RJ, Flynn PM. Recipients of vaccine against the 1976 “swine flu” have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis2010; 50:14871492.
  • 9
    Xie H, Li X, Gao J et al. Revisiting the 1976 “swine flu” vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice. Clin Infect Dis2011; 53:11791187.
  • 10
    Wang W, Anderson CM, De Feo CJ et al. Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2. PLoS Pathog2011;7:e1002081.
  • 11
    Ellebedy AH, Ducatez MF, Duan S et al. Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. Vaccine2011; 29:33353339.
  • 12
    Del Giudice G, Stittelaar KJ, van Amerongen G et al. Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci Transl Med2009; 1:12re1.
  • 13
    Manicassamy B, Medina RA, Hai R et al. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog2010; 6:e1000745.
  • 14
    Labrosse B, Tourdjman M, Porcher R et al. Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay. PLoS ONE2010; 5:e11036.
  • 15
    Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet2010; 375:4148.
  • 16
    Lee VJ, Tay JK, Chen MI et al. Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains. Vaccine2010; 28:68526857.
  • 17
    Xie H, Jing X, Li X et al. Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS ONE2011; 6:e16650.
  • 18
    Schmeisser F, Adamo JE, Blumberg B et al. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Vaccine2012; 30:34133422.
  • 19
    Schmeisser F, Vodeiko GM, Lugovtsev VY, Stout RR, Weir JP. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Vaccine2010; 28:24422449.
  • 20
    Earl P, Cooper N, Wyatt L, Moss B, Carroll M. Preparation of cell cultures and vaccinia virus stocks; in Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith J et al. (eds): Current Protocols in Molecular Biology. New York: John Wiley and Sons, Inc., 1998; 16.16.116.16.13.
  • 21
    Palmer DF, Coleman MT, Dowdle WR, Schild GC. Advanced Laboratory Techniques for Influenza Diagnosis. Washington, DC: U.S. Department of Health, Education and Welfare, 1975.
  • 22
    Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol1999; 37:937943.
  • 23
    Wang W, Castelan-Vega JA, Jimenez-Alberto A, Vassell R, Ye Z, Weiss CD. A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. Virology2010; 407:374380.
  • 24
    Wang W, Butler EN, Veguilla V et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods2008; 153:111119.
  • 25
    Wang W, Xie H, Ye Z, Vassell R, Weiss CD. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. J Virol Methods2010; 165:305310.
  • 26
    Gerhard W, Webster RG. Antigenic drift in influenza A viruses. I. Selection and characterization of antigenic variants of A/PR/8/34 (HON1) influenza virus with monoclonal antibodies. J Exp Med1978; 148:383392.
  • 27
    Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science2010; 328:357360.
  • 28
    Wang Y, Geer LY, Chappey C, Kans JA, Bryant SH. Cn3D: sequence and structure views for Entrez. Trends Biochem Sci2000; 25:300302.
  • 29
    Terajima M, Cruz J, Co MD et al. Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol2012; 85:1346313467.
  • 30
    Beebe DP, Schreiber RD, Cooper NR. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. J Immunol1983; 130:13171322.
  • 31
    Reno PW, Hoffmann EM. Enhancement of hemagglutination inhibition by complement. Infect Immun1972; 6:945951.
  • 32
    Feng JQ, Mozdzanowska K, Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol2002; 76:13691378.
  • 33
    Mozdzanowska K, Feng J, Eid M, Zharikova D, Gerhard W. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology2006; 352:418426.
  • 34
    Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell1982; 31(2 Pt 1):417427.
  • 35
    Gerhard W, Yewdell J, Frankel ME, Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature1981; 290:713717.
  • 36
    Krause JC, Tumpey TM, Huffman CJ et al. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol2010; 84:31273130.
  • 37
    World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012–2013 northern hemisphere influenza season. Available at http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf (Accessed 13 Junel 2012).
  • 38
    Strengell M, Ikonen N, Ziegler T, Julkunen I. Minor changes in the hemagglutinin of influenza A(H1N1)2009 virus alter its antigenic properties. PLoS ONE2011; 6:e25848.
  • 39
    Ilyushina NA, Khalenkov AM, Seiler JP et al. Adaptation of pandemic H1N1 influenza viruses in mice. J Virol2010; 84:86078616.
  • 40
    Ye J, Sorrell EM, Cai Y et al. Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype?PLoS Pathog2010; 6:e1001145.